JPH10503494A - インフルエンザウイルスのサブユニット複合体 - Google Patents
インフルエンザウイルスのサブユニット複合体Info
- Publication number
- JPH10503494A JPH10503494A JP8505882A JP50588296A JPH10503494A JP H10503494 A JPH10503494 A JP H10503494A JP 8505882 A JP8505882 A JP 8505882A JP 50588296 A JP50588296 A JP 50588296A JP H10503494 A JPH10503494 A JP H10503494A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- virus
- group
- carrier
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.細胞性材料に関連するタンパク質の複合体を形成する方法であって、 末端領域に少なくともひとつのチオエステル基を有し、該細胞性材料から分 離したタンパク質を提供し、 前記タンパク質を処理して少なくともひとつの該チオエステル基から少なく ともひとつの遊離のスルフヒドリル基を形成し、さらに、 少なくともひとつの遊離の該スルフヒドリル基を介した結合により、スルフ ヒドリル基を有するタンパク質とキャリヤー分子とを架橋する ことを特徴とする方法。 2.前記細胞性材料がウイルスであることを特徴とする請求の範囲第1項記載の 方法。 3.前記タンパク質が、界面活性剤抽出によってウイルスから分離されたもので あることを特徴とする請求の範囲第2項記載の方法。 4.インフルエンザウイルスの赤血球凝集素(HA)タンパク質の複合体を形成 する方法であって、 インフルエンザウイルスから分離されたトランスメンブレンおよびエンドド メインを有する全HAタンパク質を形成し、 該全HAタンパク質を処理してタンパク質のエンドドメイン内に遊離のスル フヒドリル基を形成し、さらに、 遊離の該スルフヒドリル基を介し、該HAタンパク質に対して免疫応答を示 すことができるようなキャリヤー分子に、スルフヒドリル基含有HAタンパク質 を架橋する ことを特徴とする方法。 5.インフルエンザウイルスからの全HAタンパク質の形成が、インフルエンザ ウイルスから非変性界面活性剤抽出を行うことにより全HAタンパク質を得るこ とを特徴とする請求の範囲第4項記載の方法。 6.前記非変性界面活性剤抽出において、オクチル−β−グルコシドまたはコリ ン酸ナトリウムを用いることを特徴とする請求の範囲第5項記載の方法。 7.分離された全HAタンパク質を処理して少なくともひとつの遊離のスルフヒ ドリル基を形成するにあたり、ヒドロキシルアミンを用いることを特徴とする請 求の範囲第4項記載の方法。 8.前記キャリヤー分子が、架橋剤分子を介して前記全HAタンパク質が結合し ている遊離のスルフヒドリル基を有する全HAタンパク質を含むことを特徴とす る請求の範囲第4項記載の方法。 9.前記架橋剤分子がビスマレイミド化合物であることを特徴とする請求の範囲 第8項記載の方法。 10.前記キャリヤー分子が、異種ニ機能性架橋剤分子を介して前記全HAタンパ ク質に結合したキャリヤータンパク質または炭水化物を含むことを特徴とする請 求の範囲第4項記載の方法。 11.前記キャリヤー分子または炭水化物がジフテリア毒素、破傷風毒素またはイ ンフルエンザNPタンパク質を含むことを特徴とする請求の範囲第10項記載の方 法。 12.前記異種ニ機能性架橋剤がマレイミド−N−ヒドロキシスクシンイミドエス テルを含むことを特徴とする請求の範囲第11項記載の方法。 13.前記複合体がワクチンとして製剤化されることを特徴とする請求の範囲第1 項記載の方法。 14.前記複合体がワクチンとして製剤化されることを特徴とする請求の範囲第4 項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US280,463 | 1994-07-26 | ||
US08/280,463 US5612037A (en) | 1994-07-26 | 1994-07-26 | Influenza virus subunit conjugates |
PCT/US1995/009235 WO1996003145A1 (en) | 1994-07-26 | 1995-07-20 | Influenza virus subunit conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10503494A true JPH10503494A (ja) | 1998-03-31 |
JP4024849B2 JP4024849B2 (ja) | 2007-12-19 |
Family
ID=23073201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50588296A Expired - Fee Related JP4024849B2 (ja) | 1994-07-26 | 1995-07-20 | インフルエンザウイルスのサブユニット複合体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5612037A (ja) |
EP (1) | EP0810876B1 (ja) |
JP (1) | JP4024849B2 (ja) |
AT (1) | ATE394120T1 (ja) |
AU (1) | AU707143B2 (ja) |
CA (1) | CA2194183A1 (ja) |
DE (1) | DE69535750D1 (ja) |
FI (1) | FI970277A0 (ja) |
IL (1) | IL114666A (ja) |
NO (1) | NO319525B1 (ja) |
WO (1) | WO1996003145A1 (ja) |
ZA (1) | ZA955945B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014054712A1 (ja) * | 2012-10-05 | 2014-04-10 | デンカ生研株式会社 | インフルエンザウイルスのヘムアグルチニンの測定方法 |
JPWO2015056713A1 (ja) * | 2013-10-15 | 2017-03-09 | 国立大学法人 東京大学 | c−Metタンパク質アゴニスト |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE422364T1 (de) | 1998-12-17 | 2009-02-15 | Sanofi Pasteur Ltd | Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält |
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
WO2002026252A1 (fr) * | 2000-08-10 | 2002-04-04 | Tsinghua University | Vaccin contre le virus de la grippe et son procede de preparation |
DE60323936D1 (de) * | 2002-01-14 | 2008-11-20 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
JP4800614B2 (ja) * | 2002-07-19 | 2011-10-26 | ザ ジェネラル ホスピタル コーポレイション | オキシム結合体、およびそれらの形成および使用のための方法 |
JP2006519775A (ja) * | 2003-03-07 | 2006-08-31 | メルク エンド カムパニー インコーポレーテッド | インフルエンザウイルスワクチン |
EP1667726B1 (en) | 2003-09-05 | 2011-05-04 | The General Hospital Corporation | Polyacetal drug conjugates as release system |
US20060190188A1 (en) * | 2005-01-25 | 2006-08-24 | Nauta Jozef J | Methods and systems for determining lot consistency |
CA2552596A1 (en) * | 2005-08-09 | 2007-02-09 | Solvay Pharmaceuticals B.V. | Methods and systems for determining mid-value titers |
EP2476432B1 (en) * | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
CA2697373C (en) * | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
WO2009128951A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of respiratory synctial virus proteins and methods of use |
WO2010068759A1 (en) * | 2008-12-10 | 2010-06-17 | Mersana Therapeutics, Inc. | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
CN104203275A (zh) | 2010-06-09 | 2014-12-10 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4762913A (en) * | 1973-05-07 | 1988-08-09 | The Ohio State University | Antigenic modification of polypeptides |
EP0270295A3 (en) * | 1986-12-03 | 1989-08-02 | Connaught Laboratories Limited | Conjugate vaccine |
US5354554A (en) * | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
NZ240369A (en) * | 1990-10-30 | 1993-09-27 | Daiichi Seiyaku Co | Muramyl dipeptide derivatives and vaccine compositions |
-
1994
- 1994-07-26 US US08/280,463 patent/US5612037A/en not_active Expired - Lifetime
-
1995
- 1995-07-17 ZA ZA955945A patent/ZA955945B/xx unknown
- 1995-07-19 IL IL11466695A patent/IL114666A/xx active IP Right Revival
- 1995-07-20 AU AU32342/95A patent/AU707143B2/en not_active Ceased
- 1995-07-20 CA CA002194183A patent/CA2194183A1/en not_active Abandoned
- 1995-07-20 JP JP50588296A patent/JP4024849B2/ja not_active Expired - Fee Related
- 1995-07-20 EP EP95928672A patent/EP0810876B1/en not_active Expired - Lifetime
- 1995-07-20 DE DE69535750T patent/DE69535750D1/de not_active Expired - Fee Related
- 1995-07-20 AT AT95928672T patent/ATE394120T1/de not_active IP Right Cessation
- 1995-07-20 WO PCT/US1995/009235 patent/WO1996003145A1/en active Application Filing
-
1997
- 1997-01-09 NO NO19970080A patent/NO319525B1/no not_active IP Right Cessation
- 1997-01-23 FI FI970277A patent/FI970277A0/fi unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014054712A1 (ja) * | 2012-10-05 | 2014-04-10 | デンカ生研株式会社 | インフルエンザウイルスのヘムアグルチニンの測定方法 |
US10365277B2 (en) | 2012-10-05 | 2019-07-30 | Denka Seiken Co., Ltd. | Method for measuring hemagglutinin from influenza virus |
JPWO2015056713A1 (ja) * | 2013-10-15 | 2017-03-09 | 国立大学法人 東京大学 | c−Metタンパク質アゴニスト |
US9994616B2 (en) | 2013-10-15 | 2018-06-12 | The University Of Tokyo | c-Met protein agonist |
Also Published As
Publication number | Publication date |
---|---|
ATE394120T1 (de) | 2008-05-15 |
FI970277A (fi) | 1997-01-23 |
NO970080L (no) | 1997-01-09 |
AU3234295A (en) | 1996-02-22 |
ZA955945B (en) | 1996-02-21 |
FI970277A0 (fi) | 1997-01-23 |
EP0810876A1 (en) | 1997-12-10 |
IL114666A (en) | 1999-12-22 |
JP4024849B2 (ja) | 2007-12-19 |
AU707143B2 (en) | 1999-07-01 |
WO1996003145A1 (en) | 1996-02-08 |
EP0810876A4 (en) | 2002-10-23 |
DE69535750D1 (de) | 2008-06-19 |
EP0810876B1 (en) | 2008-05-07 |
NO319525B1 (no) | 2005-08-22 |
US5612037A (en) | 1997-03-18 |
NO970080D0 (no) | 1997-01-09 |
CA2194183A1 (en) | 1996-02-08 |
IL114666A0 (en) | 1995-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4024849B2 (ja) | インフルエンザウイルスのサブユニット複合体 | |
EP0180564B1 (en) | Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents | |
CA1340956C (en) | Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines | |
EP0245078B1 (en) | Enhancement of antigen immunogenicity | |
EP0006916B1 (en) | Immunological preparations incorporating mhc antigens and their production | |
EP0191536B1 (en) | Synthetic immunogen | |
JPH0347253B2 (ja) | ||
EP1015027B1 (en) | Process for preparing conjugate vaccines including free protein | |
JPH0825900B2 (ja) | 細菌由来中性多糖類と免疫原性タン白との安定な、共有結合された多糖―タンパク質結合体、該結合体の製造方法並びに該結合体を含む医薬組成物 | |
JP2008201793A (ja) | Neisseriameningitidis血清型B複合糖質およびその使用法 | |
CA1206094A (en) | Synthetic antigenic composition and process for making same | |
EP0894008B1 (en) | Method of producing immunogenic products and vaccines | |
JPH05506234A (ja) | ワクチン組成物 | |
JPH07116055B2 (ja) | 合成ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060829 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070918 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071004 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101012 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |